Trial · NCT04124965
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rozanolixizumab ~7 mg/kg | 76.0 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rozanolixizumab ~10 mg/kg | 78.6 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication | Rozanolixizumab ~7 mg/kg | 6.0 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication | Rozanolixizumab ~10 mg/kg | 0 | percentage of participants | ||
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 5 | -2.7 | Standard Deviation 3.3 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 5 | -3.2 | Standard Deviation 3.8 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 7 | -2.7 | Standard Deviation 3.8 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 7 | -3.7 | Standard Deviation 3.4 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 9 | -2.8 | Standard Deviation 3.4 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 9 | -3.4 | Standard Deviation 3.7 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 13 | -3.1 | Standard Deviation 3.4 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 13 | -3.9 | Standard Deviation 4.0 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 17 | -2.8 | Standard Deviation 3.3 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 17 | -4.0 | Standard Deviation 3.9 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 21 | -3.0 | Standard Deviation 3.4 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 21 | -4.1 | Standard Deviation 4.3 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 25 | -2.7 | Standard Deviation 3.0 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 25 | -3.7 | Standard Deviation 4.7 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~7 mg/kg | Week 29 | -2.8 | Standard Deviation 2.1 | units on a scale |
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods | Rozanolixizumab ~10 mg/kg | Week 29 | -3.6 | Standard Deviation 4.3 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04124965/results